This trial is active, not recruiting.

Condition gastric cancer
Sponsor University of Zurich
Start date August 2011
End date March 2016
Trial size 150 participants
Trial identifier NCT01456455, UGICNS


Descriptive registry to investigate frequency of HER-2 positive gastric cancer involving CNS.

Exploration of additional prognostic factors for brain involvement from gastric cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort

Primary Outcomes

HER2 Status
time frame: 2 years

Secondary Outcomes

Outcome according to HER2 Status
time frame: 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: - in order to be eligible for the study, the diagnosis of gastric cancer and/or lower esophageal cancer must be confirmed histologically. CNS involvement must be confirmed either via independent neuroradiological and/or positive CSF cytology. Exclusion criteria: - Patients whose diagnosis is not confirmed upon pathological review or where the CNS involvement cannot be confirmed after neuroradiological review will be excluded from this study.

Additional Information

Official title Registry of Gastric Cancer and Brain Metastases
Principal investigator Silvia Hofer, MD
Description HER2 Status E-Cadherin Status
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by University of Zurich.